Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer:

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer: Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Therapeutic Advances in Medical Oncology SAGE

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer:

Loading next page...
 
/lp/sage/gastric-cancer-and-trastuzumab-first-biologic-therapy-in-gastric-iRsDNOrwbB

References (31)

Publisher
SAGE
Copyright
Copyright © 2020 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
ISSN
1758-8359
eISSN
1758-8359
DOI
10.1177/1758834012469429
Publisher site
See Article on Publisher Site

Abstract

Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and multimodality therapy has shown some benefit in the treatment of gastric cancer. Current therapies for gastric cancer have their limitations; thus, we are in need of newer treatment options including targeted therapies. Here, we review the biologic therapy with trastuzumab in human epidermal growth factor receptor 2 (HER2)+ gastric cancer.

Journal

Therapeutic Advances in Medical OncologySAGE

Published: Jan 4, 2013

Keywords: gastric cancer,trastuzumab

There are no references for this article.